COMPETITIVENESS AND DEVELOPMENT PHARMACEUTICAL INDUSTRY OF KAZAKHSTAN

The purpose of this study to determine the degree of influence of various economic indicators of the competitiveness of the pharmaceutical industry of Kazakhstan and define the growth factors in the conditions of the Common Market of the drug. The work revealed the factors affecting the production of the main pharmaceutical products of the Republic of Kazakhstan, from the very formation of the country’s independence. That is, the indicators for 1990-2018 are analyzed. The study was conducted using the methods of economic and mathematical modeling, statistical and comparative analysis. A detailed analysis of the development of the pharmaceutical industry was carried out, as well as the degree of influence of factors such as: GDP of the Republic of Kazakhstan, per capita GDP, population, wage, average monthly nominal wage of one employee, investment in fixed assets, investment in fixed assets, farm, was estimated. industries, commodity turnover in foreign currency (export), commodity circulation in foreign currency (import), industry in general, manufacturing industry in general, indices of industrial production pharm. industry and the number of operating enterprises and pharmaceutical production. products. The results of the study allow us to conclude which of these factors significantly strengthens the competitive position of the domestic pharmaceutical industry. These results are very important in making decisions and developing the pharmaceutical industry of Kazakhstan in the context of creating a Common Market of the drug within the EAEU.

1. Фармацевтический рынок Казахстана: история, основные направления развития и текущее состояние, отчет AEQUITAS, Алматы, 2015. [Электронный ресурс]. URL: http://aequitas. kz/upload/files/brochures/%D0%9E%D0%B1%D0 %B7%D0%BE%D1%80%20%D1%84%D0%B0% D1%80%D0%BC%D0%B0%D1%86%D0%B5%D 0%B2%D1%82%D0%B8%D1%87%D0%B5%D1 %81%D0%BA%D0%BE%D0%B3%D0%BE%20 %D1%80%D1%8B%D0%BD%D0%BA%D0%B0%20 %D0%9A%D0%B0%D0%B7%D0%B0%D1%85%D1 %81%D1%82%D0%B0%D0%BD%D0%B0.pdf (дата обращения: 18.04.2019).

2. Соколов, Б. И. Фармацевтический рынок: структурные особенности в России /Б.И. Соколов, А.А. Лин, А.С. Орлов // Проблемы современной экономики. - 2012. - №4 (44). - С.336-341.

3. Andrey Bekarev A., Bekareva S. Competitiveness of national pharmaceutical industry: The Russian case. Journal of Chemical and Pharmaceutical Research, 2015, 7(5), p. 710-715

4. Yu, Z.-J., Chu, S.-Z. Study of relationship between the competitiveness of China’s pharmaceutical manufacturing industry and innovative drug research and development. (2018) Chinese Journal of New Drugs, 27 (3), PP. 279-284 [Electronic source] URL: https://www.scopus.com/inward/record.uri?eid=2-s2.0- 85045749670&partnerID=40&md5=2102a2ede6ea30f 605cd1afa1268b75b

5. Guan, J.C., Yam, R.C.M., Mok, C.K., Ma, N. A study of the relationship between competitiveness and technological innovation capability based on DEA models.(2006) European Journal of Operational Research, 170 (3), pp. 971-986. [Electronic source] URL: https://www.scopus.com/inward/record.uri?eid=2-s2.0- 27744483854&doi=10.1016%2fj.ejor.2004.07.054&pa rtnerID=40&md5=1c114dc39f7c6807ff241731d7e2ab 8d

6. Rasekh HR, Mehralian GH, Vatankhah-Mohammadabadi AA. Situation analysis of R&D activities: an empirical study in Iranian pharmaceutical companies. Iran J Pharm Res. 2012, 11 p.: 1013-1025.

7. Demirel P, Mazzucato M: Innovation and firm growth: is R&D worth it?. Industry and Innovation. 2012, 19. p. 45-62.

8. Cai, J., Zhao, H., Coyte, P.C. The effect of intellectual property rights protection on the international competitiveness of the pharmaceutical manufacturing industry in China.(2018) Engineering Economics, 29 (1), pp. 62-71. [Electronic source] URL: https://www.scopus.com/inward/record.uri?eid=2-s2.0- 85042801540&doi=10.5755%2fj01.ee.29.1.16878&pa rtnerID=40&md5=4f3d78f4562a535d4cd56823688d41 6d

9. Allred, B.B., Park, W.G. Patent rights and innovative activity: Evidence from national and firm-level data. 2007. Journal of International Business Studies, 38 (6), pp. 878-900.

10. Galovic, T. The international competitiveness of the pharmaceutical industry within 21 OECD countries. (2015). Ekonomski Vjesnik/ Econviews: Review of Contemporary Business, Entrepreneurship and Economic Issues,28 (1),p. 225-241.http:// [Electronic source] URL: hrcak.srce. hr/140840

11. Grace, C. The effect of changing intellectual property on pharmaceutical industry prospects in India and China. 2004. DFID Health Systems Resource Centre, pp. 1-68http:// [Electronic source] URL: www. who.int/hiv/amds/Grace2China.pdf?ua=1

12. Lanoszka, A. The global politics of intellectual property rights and pharmaceutical drug policies in developing countries. 2003. International Political Science Review, 24 (2), pp. 181-197.

13. Franculino, K.A.S., Gomes, R. Public policies and competitiveness in the pharmaceutical industry: The case of Brazil and India.2017. Espacios, 38 (26), [Electronic source] URL: https://www.scopus. com/inward/record.uri?eid=2-s2.0-85020183279&partn erID=40&md5=ab6831240300f424f4591bc5de66ecd4

14. Nishida, A.L., Costa, C.K.F., Bondezan, K.L., Ribeiro, V.S. Regulation of the pharmaceutical industry in Brazil and its consequences on the exports and imports in Brazil between 1997 and 2014 [Regulação da indústriafarmacêutica no Brasil e seusdesdobramentossobre a pauta de exportações e importaçõesno Brasilentre 1997 e 2014](2017) Espacios, 38 (19), [Electronic source] URL: ttps://www.scopus. com/inward/record.uri?eid=2-s2.0-85018778040&partn erID=40&md5=296c8ec 43ed4c9baf557cc8582c54181

15. Topleninov, E.O., Elshin, L.A.Methods for identifying the priority development fields of the regional pharmaceutical cluster based on the mechanisms of using the Balanced Scorecard.2017. Espacios, 38 (33), [Electronic source] URL: https://www.scopus.com/ inward/record.uri?eid=2-s2.0-85026775992&partnerID =40&md5=054cacdcdb4f74593cccf3f52ff22152

16. Kharub, M., Sharma, R.Comparative analyses of competitive advantage using Porter diamond model (the case of MSMEs in Himachal Pradesh.2017. Competitiveness Review, 27 (2), p. 132-160. [Electronic source] URL: ttps://www.scopus.com/inward/record. uri?eid=2-s2.0-85015652789&doi=10.1108%2fCR-02-2016-007&partnerID=40&md5=c40e6692a2aa063aa5c c54ae009f2e6e

17. Конкурентоспособность национальной экономики: критерии оценки и пути повышения / Сабден О., Кошанов Л.К., Хусаинов Б.Д., Днишев Ф.М., Додонов В.Ю., Аханов С.А., Нурланова Н.K., Альжанова Ф.Г. Экономика. Избранные труды. - Алматы: Институт экономики КН МОН РК, 2011. Т. IX. - 200 с.

18. Дуламбаева Р. Т. Конкурентное развитие экономики Казахстана: противоречия и перспективы // Молодой ученый. - 2009. - № 10. - С. 128-131. - [Электронный ресурс]. URL: https://moluch.ru/archive/10/766/ (дата обращения: 20.04.2019).

19. Сагадиев К.А. Проблемы конкурентоспособности национальной экономики // Проблемы устойчивого экономического развития в условиях глобализации: в 2-х т. / Отв. ред. М.Б. Кенжегузин. - Алматы: ИЭ МОН РК, 2003. - Т.1.

20. Джантемирова Д. М. Пути повышения конкурентоспособности в обрабатывающей промышленности Казахстана: дисс. PhD - «Экономика, теория управления». - Алматы, 2010. -124 с.

21. Renee J. G. Arnold. Pharmacoeconomics: From Theory to Practice (Drug Discovery) Boca Raton, FL: CRC Press. 2009: 263-273

22. Ягудина Р. И., Куликов А. Ю., Новиков И. В.Современная методология анализа чувствительности в фармакоэкономических исследованиях // Фармакоэкономика. - 2010. - № 4. - Т. 3.

23. Бизнес-форум фармацевтических компаний Индии и Казахстана // Казахстанский фармацевтический вестник. - 2010. - № 24 (507). Электронный ресурс, [режим доступа] http:// pharmnews.kz/ ru/ article/ biznes-forum-farmacevticheskih-kompaniy-indii-i-kazahstana_10925

24. Анализ фармацевтического рынка Казахстана - 2016. Маркетинговая компания “ИМСИ Elim”, [Электронный ресурс]. URL: http:// www.marketingcenter.kz/2016/05-20-kazakhstan-analiz-farmacevticheskogo-rynka.html (дата обращения: 15.05.2019).

25. Бидарова Ф. Н. (ред.) Современная фармация: проблемы и перспективы развития // Материалы V Межрегиональной научно-практической конференции с международным участием (29÷30 мая 2015 г.). - Владикавказ, 2015. - 465 с.

26. Нурумбетов Д., Минздрав сэкономил 80 млрд тенге с запуска СК «Фармация»,КАПИТАЛ центр деловой информации. Электронный ресурс, [режим доступа] https://kapital.kz/economic/76758/ minzdrav-sekonomil-80-mlrd-tenge-s-zapuska-sk- farmaciya.html 22.03.2019